Issie Kirby
Stock Analyst at Redburn Atlantic
(2.91)
# 1,345
Out of 4,829 analysts
7
Total ratings
100%
Success rate
49.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Upgrades: Buy | $85 → $115 | $84.65 | +35.85% | 2 | Feb 3, 2025 | |
| ALC Alcon | Upgrades: Neutral | n/a | $94.87 | - | 1 | Oct 10, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Buy | $60 | $23.41 | +156.30% | 1 | May 30, 2024 | |
| PODD Insulet | Initiates: Buy | $235 | $315.88 | -25.60% | 1 | May 30, 2024 | |
| COO The Cooper Companies | Upgrades: Buy | $125 | $84.27 | +48.33% | 2 | Mar 19, 2024 |
DexCom
Feb 3, 2025
Upgrades: Buy
Price Target: $85 → $115
Current: $84.65
Upside: +35.85%
Alcon
Oct 10, 2024
Upgrades: Neutral
Price Target: n/a
Current: $94.87
Upside: -
Tandem Diabetes Care
May 30, 2024
Initiates: Buy
Price Target: $60
Current: $23.41
Upside: +156.30%
Insulet
May 30, 2024
Initiates: Buy
Price Target: $235
Current: $315.88
Upside: -25.60%
The Cooper Companies
Mar 19, 2024
Upgrades: Buy
Price Target: $125
Current: $84.27
Upside: +48.33%